Samsung Biologics Co Ltd
Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates through Contract Development and Manufacturing Organization (CDMO), and Biopharmaceutical Development and Commercialization segments. Its development services include late discovery, cell line de… Read more
Samsung Biologics Co Ltd (207940) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.051x
Based on the latest financial reports, Samsung Biologics Co Ltd (207940) has a cash flow conversion efficiency ratio of 0.051x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩619.30 Billion) by net assets (₩12.18 Trillion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Samsung Biologics Co Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Samsung Biologics Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Samsung Biologics Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Samsung Biologics Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NWOEF
PINK:NWOEF
|
0.077x |
|
Shandong Hualu Hengsheng Chemical Co Ltd
SHG:600426
|
0.028x |
|
Cullen/Frost Bankers Inc
NYSE:CFR
|
0.056x |
|
Auckland International Airport Limited
PINK:ACKDF
|
0.024x |
|
Wayfair Inc
NYSE:W
|
-0.056x |
|
TENARIS S.A. DL 1
F:TW10
|
N/A |
|
Sanrio Company Ltd
PINK:SNROF
|
0.282x |
|
National Fuel Gas Company
NYSE:NFG
|
0.077x |
Annual Cash Flow Conversion Efficiency for Samsung Biologics Co Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of Samsung Biologics Co Ltd from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩10.90 Trillion | ₩1.66 Trillion | 0.152x | -10.23% |
| 2023-12-31 | ₩9.83 Trillion | ₩1.67 Trillion | 0.169x | +59.79% |
| 2022-12-31 | ₩8.98 Trillion | ₩953.05 Billion | 0.106x | +16.46% |
| 2021-12-31 | ₩4.99 Trillion | ₩454.60 Billion | 0.091x | +107.27% |
| 2020-12-31 | ₩4.60 Trillion | ₩202.09 Billion | 0.044x | +1784.58% |
| 2019-12-31 | ₩4.35 Trillion | ₩10.15 Billion | 0.002x | +129.35% |
| 2018-12-31 | ₩4.16 Trillion | ₩-33.02 Billion | -0.008x | -121.09% |
| 2017-12-31 | ₩3.98 Trillion | ₩149.82 Billion | 0.038x | +345.46% |
| 2016-12-31 | ₩4.08 Trillion | ₩-62.66 Billion | -0.015x | +83.96% |
| 2015-12-31 | ₩2.77 Trillion | ₩-265.51 Billion | -0.096x | +44.27% |
| 2014-12-31 | ₩630.73 Billion | ₩-108.30 Billion | -0.172x | -- |